Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myeloproliferative Disorders × Dabigatran × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 5 Venous Thromboembolism 4 Venous Thrombosis 3 Pulmonary Embolism 3 Thrombosis 1 Prostatic Neoplasms 1 Myeloproliferative Disorders 1 Embolism 1 Cushing Syndrome 1 Colorectal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Advanced Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 77 fludarabine phosphate 76 Peripheral Blood Stem Cell Transplantation 60 Mycophenolic Acid 50 Whole-Body Irradiation 49 Busulfan 48 Tacrolimus 46 Antilymphocyte Serum 40 fludarabine 39 Cyclosporine 38 Filgrastim 34 Cytarabine 30 ruxolitinib 29 Methotrexate 29 Melphalan 29 Radiotherapy 22 Etoposide 21 Azacitidine 20 Methylprednisolone 18 Cord Blood Stem Cell Transplantation 15 Biopsy 15 Sirolimus 14 Decitabine 14 thymoglobulin 13 Specimen Handling 13 Granulocyte Colony-Stimulating Factor 13 Flow Cytometry 13 Alemtuzumab 13 venetoclax 11 Cyclosporins 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04192916 2021-02-21

MPN-DOACs

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡